Overview

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Status:
Completed

Trial end date:
2021-01-22

Target enrollment:

Participant gender:

Summary

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects with Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma China, Inc.

Treatments:

Antibodies, Monoclonal